<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065698</url>
  </required_header>
  <id_info>
    <org_study_id>REVC005</org_study_id>
    <secondary_id>2019-000976-40</secondary_id>
    <nct_id>NCT04065698</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of RV521 Formulations</brief_title>
  <acronym>C19007</acronym>
  <official_title>An Open-label, Single Dose, Three Sequence Study in Healthy Adult Volunteers to Evaluate the Pharmacokinetics, Safety and Tolerability of RV521 Administered as the Drug in Capsule Formulation in the Fed State and the Dry Powder Blend Formulation Dispersed in Water in the Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReViral Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReViral Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aims of the study are to assess the pharmacokinetics and safety of single doses of
      RV521 administered as two different formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2019</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (tmax) for RV521</measure>
    <time_frame>Baseline to study day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half life (t1/2) for RV521</measure>
    <time_frame>Baseline to study day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for RV521</measure>
    <time_frame>Baseline to study day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to last detectable plasma concentration (AUC0-t) for RV521</measure>
    <time_frame>Baseline to study day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for RV521</measure>
    <time_frame>Baseline to study day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events as assessed by CTCAE V5.0</measure>
    <time_frame>Screening to final study visit (performed at 7 days following the last dose of any intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinically significant changes in laboratory safety tests (haematology, chemistry, coagulation and urinalysis)</measure>
    <time_frame>Screening to final study visit (performed at 7 days following the last dose of any intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with morphological and/or rhythm abnormalities on ECG</measure>
    <time_frame>Screening to final study visit (performed at 7 days following the last dose of any intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinically significant changes in ECG time intervals (PR, QRS, QT and QTc intervals)</measure>
    <time_frame>Screening to final study visit (performed at 7 days following the last dose of any intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinically significant changes in vital signs (systolic blood pressure, diastolic blood pressure and pulse rate)</measure>
    <time_frame>Screening to final study visit (performed at 7 days following the last dose of any intervention)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>RV521</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three single 200 mg oral doses of RV521 administered on Day 1, Day 5 and Day 9 as either the drug in capsule (1 dosing occasion) or the dry powder blend dispersed in water (2 dosing occasions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV521</intervention_name>
    <description>Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.</description>
    <arm_group_label>RV521</arm_group_label>
    <other_name>Sisunatovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to comply with protocol defined contraception requirements

          -  In good health with no history of major medical conditions

          -  A body mass index (BMI) of 18-25 kg/m^2, inclusive

        Exclusion Criteria:

          -  Evidence of any clinically significant or currently active major medical condition

          -  Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab),
             or human immunodeficiency virus antibody (HIV Ab) at screening

          -  Not willing to comply with protocol defined restrictions for intake of drugs of abuse,
             alcohol, nicotine-containing products, medication (prescription, OTC, herbal,
             vitamins/minerals etc) and specified food and drink products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

